BTIG analyst Thomas Shrader has maintained their neutral stance on ATHA stock, giving a Hold rating on February 28.
Thomas Shrader has given his Hold rating due to a combination of factors surrounding Athira Pharma’s current developments and future prospects. The company is focusing on ATH-1105, a molecule that appears to be more promising than its predecessor, FOSGO, particularly in the context of ALS treatment. While ATH-1105 has shown a favorable safety and tolerability profile in a recent Phase 1 study, the efficacy data is still pending, with results expected in the first half of 2026.
Moreover, the company’s strategy to measure Nf-L levels in upcoming ALS studies is noteworthy, as this biomarker is increasingly recognized for its correlation with disease progression. Despite the potential of ATH-1105, the company remains in a ‘prove it’ phase, and the restructuring efforts have provided a financial runway to support operations until the data readout. Given these uncertainties and the need for further validation, a Hold rating seems appropriate at this stage.
According to TipRanks, Shrader is a 4-star analyst with an average return of 4.8% and a 36.70% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Denali Therapeutics, Arcturus Therapeutics, and Alector.